SCHEMBL369097

SCHEMBL369097

CC(C)(C)c1noc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.40
ALOX5AP P20292 4/20 0.35
EIF2AK3 Q9NZJ5 2/20 0.32
RET P07949 3/20 0.31
NEK7 Q8TDX7 4/20 0.31
PRMT5 O14744 2/20 0.31
WDR77 Q9BQA1 2/20 0.31
RIPK2 O43353 1/20 0.31
PDGFRB P09619 1/20 0.31
KIT P10721 1/20 0.31
SRC P12931 1/20 0.31
FLT3 P36888 1/20 0.31
SIK1 P57059 1/20 0.31
RIPK4 P57078 1/20 0.31
DDR1 Q08345 1/20 0.31
RIPK1 Q13546 1/20 0.31
DSTYK Q6XUX3 1/20 0.31
RIPK3 Q9Y572 1/20 0.31
ADK P55263 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355771 0.84 GPR119 (0.49) GPR119
SCHEMBL356767 0.83 GPR119 (0.41) GPR119EIF2AK3RETNEK7
SCHEMBL10140674 0.79 ADK (0.34) EIF2AK3RETNEK7RIPK2PDGFRB
SCHEMBL369095 0.77 GPR119 (0.32) GPR119EIF2AK3RETNEK7RIPK2
SCHEMBL10139852 0.76 GPR119 (0.42) GPR119ALOX5APNEK7FLT3
SCHEMBL10171761 0.75 GPR119 (0.56) GPR119NEK7
SCHEMBL10140747 0.74 MALT1 (0.37) RIPK2PDGFRBKITSRCFLT3
SCHEMBL10172674 0.74 GPR119 (0.45) GPR119NEK7
SCHEMBL357038 0.74 RIPK2 (0.38) GPR119EIF2AK3RETPRMT5WDR77
SCHEMBL358364 0.73 GPR119 (0.36) GPR119RETPRMT5WDR77RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885ALOX5AP 2967/4885EIF2AK3 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.